1972—2016年启东市肾癌生存分析

doi:10.19485/j.cnki.issn2096-5087.2023.01.011

预防医学

2023, Vol. 35

Issue (1): 48-52 DOI: 10.19485/j.cnki.issn2096-5087.2023.01.011

疾病控制

本期目录 | 过刊浏览 | 高级检索

1972—2016年启东市肾癌生存分析

丁璐璐, 张永辉, 徐源佑, 陈永胜, 王军, 朱健

启东市人民医院（南通大学附属启东医院）病因室,江苏启东 226200

Survival analysis of kidney cancer in Qidong City from 1972 to 2016

DING Lulu, ZHANG Yonghui, XU Yuanyou, CHEN Yongsheng, WANG Jun, ZHU Jian

Department of Etiology, Qidong People's Hospital (The Affiliated Qidong Hospital of Nantong University), Qidong, Jiangsu 226200, China

摘要
参考文献
相关文章
Metrics

全文: PDF(814 KB)
输出: BibTeX | EndNote (RIS)

摘要目的了解1972—2016年江苏省启东市肾癌病例生存率及变化趋势,为肾癌防制提供依据。方法通过启东市肿瘤登记报告系统收集1972—2016年启东市肾癌发病资料,随访截止日期为2021年12月31日。计算肾癌观察生存率、相对生存率、标化相对生存率和年度变化百分比（APC）,分析肾癌生存率及变化趋势。结果 1972—2016年启东市肾癌发病554例,1年、3年、5年观察生存率分别为62.27%、50.54%和44.04%,相对生存率分别为64.31%、55.71%和51.93%,标化相对生存率分别为61.71%、51.90%和51.68%。肾癌5年观察生存率、相对生存率和标化相对生存率均呈上升趋势,APC值分别为2.83%（t=4.303,P=0.004）、2.82%（t=3.978,P=0.005）和3.96%（t=5.898,P=0.001）。男性肾癌5年相对生存率为53.05%,女性为50.40%,差异无统计学意义（χ²=4.872,P=0.676）。不同年龄肾癌病例5年相对生存率差异有统计学意义（χ²=35.144,P<0.001）,35~<45岁较高,为64.49%;≥75岁较低,为30.11%。结论 1972—2016年启东市肾癌病例5年生存率呈上升趋势,应对不同年龄段开展针对性防治。

	服务

	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	丁璐璐
	张永辉
	徐源佑
	陈永胜
	王军
	朱健

关键词 ：肾癌, 生存率, 生存分析

Abstract：Objective To investigate the survival rate and changing trends of kidney cancer patients in Qidong City from 1972 to 2016, so as to provide insights into kidney cancer control. Methods Data pertaining to the incidence of kidney cancer in Qidong City from 1972 to 2016 were captured from the Qidong Municipal Cancer Registration System, and the final follow-up period was December 31, 2021. The observed survival rate, relative survival rate and standardized relative survival rate of kidney cancer were calculated to analyze the survival of kidney cancer, and the trends in survival were analyzed among kidney cancer patients from 1972 to 2016 using annual percent change (APC). Results A total of 554 kidney cancer patients were reported in Qidong City from 1972 to 2016. The 1-, 3- and 5-year observed survival rates, relative survival rates and standardized relative survival rates were 62.27%, 50.54% and 44.04%; 64.31%, 55.71% and 51.93%; and 61.71%, 51.90%, and 51.68%, respectively. The 5-year observed survival rate, relative survival rate and standardized relative survival rate of kidney cancer appeared a tendency towards a rise in Qidong City from 1972 to 2016, with APC of 2.83% (t=4.303, P=0.004), 2.82% (t=3.978, P=0.005) and 3.96% (t=5.898, P=0.001), and the 5-year relative survival rate of kidney cancer was comparable between men and women (53.05% vs. 50.40%; χ²=4.872, P=0.676). There was an age-specific 5-year relative survival rate of kidney cancer (χ²=35.144, P<0.001), with the greatest among patients at ages of 35 to 44 years (64.49%) and the lowest at ages of 75 years and older (30.11%). Conclusion The 5-year survival rate of kidney cancer cases appeared a tendency towards a rise in Qidong City from 1972 to 2016. Further specific interventions, depending on age, are needed for management of kidney cancer.

Key words： kidney cancer survival rate survival analysis

收稿日期: 2022-09-02 修回日期: 2022-10-18 出版日期: 2023-01-10

中图分类号:

R736.6

基金资助:2022年南通市科技计划项目（JCZ2022050）

通信作者: 朱健,E-mail：jsqdzj8888@sina.com

作者简介: 丁璐璐,本科,病案信息技术（师）,主要从事肿瘤登记工作

引用本文:

丁璐璐, 张永辉, 徐源佑, 陈永胜, 王军, 朱健. 1972—2016年启东市肾癌生存分析[J]. 预防医学, 2023, 35(1): 48-52.
DING Lulu, ZHANG Yonghui, XU Yuanyou, CHEN Yongsheng, WANG Jun, ZHU Jian. Survival analysis of kidney cancer in Qidong City from 1972 to 2016. Preventive Medicine, 2023, 35(1): 48-52.

链接本文:

http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2023.01.011 或 http://www.zjyfyxzz.com/CN/Y2023/V35/I1/48

[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] ZHENG R S R,ZHANG S W,ZENG H M,et al.Cancer incidence and mortality in China,2016[J/OL].J Natl Cancer Cent,2022[2022-10-18].https://doi.org/10.1016/j.jncc.2022.02.002.
[3] 陈磊,徐杰茹,刘艳,等.2005—2015年中国肾癌发病趋势分析[J].华中科技大学学报(医学版),2022,51(1):58-62,67.
[4] 陈磊,徐杰茹,王冕,等.1990—2019年中国肾癌死亡趋势及其年龄-时期-队列分析[J].中华疾病控制杂志,2021,25(9):1026-1033,1111.
[5] ALLEMANI C,WEIR H K,CARREIRA H,et al.Global surveillance of cancer survival 1995-2009:analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries(CONCORD-2)[J].Lancet,2015,385(9972):977-1010.
[6] CORAZZIARI I,QUINN M,CAPOCACCIA R.Standard cancer patient population for age standardising survival ratios[J].Eur J Cancer,2004,40(15):2307-2316.
[7] 陈建国,SANKARANARAYANAN R,沈卓才,等.恶性肿瘤16 922例生存率分析[J].中华肿瘤杂志,1998,20(3):202-206.
[8] 中华人民共和国国家癌症中心.中国肿瘤登记工作指导手册(2016)[M].北京:人民卫生出版社,2016.
[9] BRAY F,COLOMBET M,MERY M,et al.Cancer incidence in five continents,vol.XI[M].Lyon:IARC Scientific Publications,2021.
[10] Finnish Cancer Registry.SURV3:windows software for relative survival analysis[EB/OL].[2022-10-18].http://www.cancerregistry.fi/surv3/2022-3-20.
[11] Division of Cancer Control and Population Sciences NCL.Joinpoint trend analysis software[EB/OL].[2022-10-18].https://surveillance.cancer.gov/joinpoint.
[12] CHEN J,ZHU J,ZHANG Y,et al.Cancer survival in Qidong between 1972 and 2011:a population-based analysis[J].Mol Clin Oncol,2017,6(6):944-954.
[13] HONG S,WON Y J,PARK Y R,et al.Cancer statistics in Korea:incidence,mortality,survival,and prevalence in 2017[J].Cancer Res Treat,2020,52(2):335-350.
[14] National Cancer Institute.Cancer stat facts:kidney and renal pelvis cancer[EB/OL].[2022-10-18].https://seer.cancer.gov /statfacts /html/kidrp.html.
[15] 李小攀,杨黎明,孙乔,等.上海市浦东新区居民肾癌患者生存率影响因素分析[J].中华肿瘤防治杂志,2013,20(21):1634-1637.
[16] KUGEL C H,DOUGLASS S M,WEBSTER M R,et al.Age correlates with response to anti-PD1,reflecting age-related differences in intratumoral effector and regulatory T-Cell populations[J].Clin Cancer Res,2018,24(21):5347-5356.
[17] CHEN W,XIA C,ZHENG R,et al.Disparities by province,age,and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China:a comparative risk assessment[J].Lancet Glob Health,2019,7(2):e257-e269.
[18] 王倩倩,徐丽.2015—2019年武义县居民恶性肿瘤死亡趋势分析[J].预防医学,2022,34(7):732-737.
[19] HOFMANN F,HWANG E C,LAM T B,et al.Targeted therapy for metastatic renal cell carcinoma[J/OL].Cochrane Database Syst Rev,2020,10[2022-10-18].https://doi.org/10.1002/14651858.CD012796.pub2.

[1]	沈蔚, 刘佳琪, 陈俊斐, 应士波, 夏海玲, 冯玲芳, 靳明英, 蒋兆强. 恶性间皮瘤36例患者生存分析[J]. 预防医学, 2022, 34(1): 66-69.
[2]	孙群露, 周宗磊, 詹志强, 涂玉山, 陈晓燕, 李咸志, 栾荣生. 宝安区50岁及以上HIV/AIDS病例生存状况分析[J]. 预防医学, 2021, 33(2): 170-173.
[3]	周涛, 李月飞, 白雪, 胡晓远, 马媛媛, 倪明健. 2005—2019年伊犁州抗病毒治疗吸毒人群HIV/AIDS病例生存分析[J]. 预防医学, 2021, 33(1): 25-30.
[4]	邱玉冰, 许琳, 杨蕊, 陈金瓯. 云南省成功治疗肺结核患者5年复发情况及影响因素分析[J]. 预防医学, 2020, 32(6): 559-562.
[5]	王斌, 龚德光, 朱洁群. 鄞州区艾滋病抗病毒治疗患者生存率及影响因素分析[J]. 预防医学, 2020, 32(4): 346-350.
[6]	杨小丹, 田春艳, 李月友, 毛照明, 贾文涛. 商洛市艾滋病抗病毒治疗病例生存率及影响因素分析[J]. 预防医学, 2020, 32(1): 18-21.
[7]	刘盼盼,陈洁,唐倩如,童思未,施丹华. 海曙区居民恶性肿瘤监测分析[J]. 预防医学, 2018, 30(6): 565-569.
[8]	徐小仙,张筱婧,周建松,楼寒梅. 211例宫颈腺癌治疗患者生存预后影响因素分析[J]. 预防医学, 2017, 29(4): 360-362.

Viewed

Full text

Abstract

Cited

Shared

Discussed